Wednesday, October 31, 2018 10:14:25 AM
https://ir.rmsmedicalproducts.com/all-sec-filings/content/0001161697-18-000509/0001161697-18-000509.pdf
below is the supplemental information concerning horton's management warrants
[SUPPLEMENTAL INFORMATION: On September 13, 2018, Horton Capital Partners Fund, LP notified RMS of its
intention to exercise the warrant, purchased on August 8, 2014 and expiring on August 8, 2019, in full at an
exercise price of $0.45 per share at a closing to take place no earlier than November 12, 2018].
Horton management continues to buy stock in the open market at these levels. This indicates a belief in the company's future and faith that the stock price will continue to appreciate.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM